Frequencies and prognostic role of KRAS and BRAF mutations in patients with localized pancreatic and ampullary adenocarcinomas

Pancreas

Volumn 41, Issue 5, 2012, Pages 759-766

  Schultz, Nicolai Aagaard ^a   Roslind, Anne ^b   Christensen, J ^c   Horn, Thomas ^b   Høgdall, Estrid ^b   Pedersen, Lisbeth N ^d   Kruhøffer, Mogens ^e   Burcharth, Flemming ^a   Wøjdemann, Morten ^a   Johansen, Julia S ^b  

^a Rigshospitalet   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e AROS Applied Biotechnology A/S   (Denmark)

Author keywords

BRAF; KRAS; Pancreatic cancer; PDAC; Prognosis

Indexed keywords

B RAF KINASE; CISPLATIN; DNA; FLUOROURACIL; GEMCITABINE; K RAS PROTEIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CODON; DNA DETERMINATION; EXON; FEMALE; FUNCTIONAL STATUS; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SMOKING; VATER PAPILLA CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; CARCINOMA, PANCREATIC DUCTAL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SMOKING;

EID: 84863644421     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31823cd9df     Document Type: Article

References (34)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049-1057.
4. Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2007;25:2607-2615.
5. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605-3610.
6. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
7. Esposito I, Friess H, Buchler MW. Carcinogenesis of cancer of the papilla and ampulla: pathophysiological facts and molecular biological mechanisms. Langenbecks Arch Surg. 2001;386:163-171.
8. Fischer HP, Zhou H. Pathogenesis of carcinoma of the papilla of Vater. J Hepatobiliary Pancreat Surg. 2004;11:301-309.
9. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157-188.
10. Genkinger JM, Spiegelman D, Anderson KE, et al. Alcohol intake and pancreatic cancer risk: a pooled analysis of fourteen cohort studies. Cancer Epidemiol Biomarkers Prev. 2009;18:765-776.
11. Koorstra JB, Hustinx SR, Offerhaus GJ, et al. Pancreatic carcinogenesis. Pancreatology. 2008;8:110-125.
12. Brune K, Hong SM, Li A, et al. Genetic and epigenetic alterations of familial pancreatic cancers. Cancer Epidemiol Biomarkers Prev. 2008;17:3536-3542.
13. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
14. Smith G, Bounds R, Wolf H, et al. Activating K-ras mutations outwith 'hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer. 2010;102:693-703.
15. Kleeff J, Michalski C, Friess H, et al. Pancreatic cancer: from bench to 5-year survival. Pancreas. 2006;33:111-118.
16. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3:459-465.
17. Repasky GA, Chenette EJ, der CJ. Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 2004;14:639-647.
18. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
19. Seth R, Crook S, Ibrahem S, et al. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer. Gut. 2009;58:1234-1241.
20. Richman SD, Seymour MT, Chambers P, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol. 2009;27:5931-5937.
21. Ogino S, Meyerhardt JA, Irahara N, et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res. 2009;15:7322-7329.
22. Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466-474.
23. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol. 2010;28:1254-1261.
24. Friess H, Kleeff J, Korc M, et al. Molecular aspects of pancreatic cancer and future perspectives. Dig Surg. 1999;16:281-290.
25. Laghi L, Orbetegli O, Bianchi P, et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene. 2002;21:4301-4306.
26. Campbell PM, Groehler AL, Lee KM, et al. K-ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res. 2007;67:2098-2106.
27. Feldmann G, Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn. 2008;10:111-122.
28. Lee J, Jang KT, Ki CS, et al. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer. 2007;109:1561-1569.
29. Immervoll H, Hoem D, Kugarajh K, et al. Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch. 2006;448:788-796.
30. Blackford A, Parmigiani G, Kensler TW, et al. Genetic mutations associated with cigarette smoking in pancreatic cancer. Cancer Res. 2009;69:3681-3688.
31. Matsubayashi H, Watanabe H, Yamaguchi T, et al. Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of vater. Cancer. 1999;86:596-607.
32. Agoff SN, Crispin DA, Bronner MP, et al. Neoplasms of the ampulla of vater with concurrent pancreatic intraductal neoplasia: a histological and molecular study. Mod Pathol. 2001;14:139-146.
33. Boeck SH, Vehling-Kaiser U, Waldschmidt D, et al. Gemcitabine plus erlonitib (GE) followed by capecitabine (C) versus capacitabine plus erlonitib (CE) followed by gemcitabine (G) in advanced pancreatic cancer (APC): a randomized, cross-over trial of the Arbeitsgemeinschaft Internistiche Onkologie (AIO). J Clin Oncol. 2010;28(18 suppl):LBA4011.
34. Kubo T, Kuroda Y, Kokubu A, et al. Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. Pancreas. 2009;38(7):e200- e206.